PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34035084-3	2021	Here, we show that VEGF-dependent release of thromboxane A2 (TXA2) triggers Ca2+ transients in tumor cells, culminating in PGE2 secretion and subsequent immune evasion in the early stages of tumorigenesis.	Thromboxane A2	45-59	vascular endothelial growth factor A	Mus musculus	19-23	
34035084-3	2021	Here, we show that VEGF-dependent release of thromboxane A2 (TXA2) triggers Ca2+ transients in tumor cells, culminating in PGE2 secretion and subsequent immune evasion in the early stages of tumorigenesis.	Thromboxane A2	61-65	vascular endothelial growth factor A	Mus musculus	19-23	
34035084-8	2021	Notably, treatment with a vascular endothelial growth factor (VEGF) receptor antagonist and an anti-VEGF antibody rapidly suppressed Ca2+ transients and reduced TXA2 and PGE2 concentrations in tumor tissues.	Thromboxane A2	161-165	vascular endothelial growth factor A	Mus musculus	26-60	
34035084-8	2021	Notably, treatment with a vascular endothelial growth factor (VEGF) receptor antagonist and an anti-VEGF antibody rapidly suppressed Ca2+ transients and reduced TXA2 and PGE2 concentrations in tumor tissues.	Thromboxane A2	161-165	vascular endothelial growth factor A	Mus musculus	62-66	
34035084-8	2021	Notably, treatment with a vascular endothelial growth factor (VEGF) receptor antagonist and an anti-VEGF antibody rapidly suppressed Ca2+ transients and reduced TXA2 and PGE2 concentrations in tumor tissues.	Thromboxane A2	161-165	vascular endothelial growth factor A	Mus musculus	100-104